Document is current
Any future updates will be listed below
-
Authors
Parikh, Sameer A. https://orcid.org/0000-0002-3221-7314
Ioannou, Nikolaos
Ramsay, Alan G. https://orcid.org/0000-0002-0452-0420
Boysen, Justin C.
Kenderian, Saad S. https://orcid.org/0000-0003-2767-3830
Rabe, Kari G. https://orcid.org/0000-0002-7313-1875
Sinha, Sutapa https://orcid.org/0000-0002-7274-9622
Braggio, Esteban https://orcid.org/0000-0003-3860-4830
Medina, Kay L. https://orcid.org/0000-0003-4188-8053
Slager, Susan L. https://orcid.org/0000-0002-5173-4712
Shanafelt, Tait D.
Kay, Neil E. https://orcid.org/0000-0002-5951-5055
-
Funding
Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (K12CA090628, K12CA090628)
Hentry J Predolin Foundation, & Janssen Pharmaceuticals
U.S. Department of Health & Human Services | NIH | National Cancer Institute (ca95241)
U.S. Department of Health & Human Services | National Institutes of Health (ca95241)
- License Information
-
More Information
Article History
Received: 10 March 2025
Revised: 10 April 2025
Accepted: 27 June 2025
First Online: 20 August 2025
Competing interests
: SAP: Research funding has been provided to the institution from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which SAP is a principal investigator. Honoraria has been provided to the institution from Pharmacyclics, Merck, AstraZeneca, Janssen, BeiGene, Genentech, Amgen, MingSight Pharmaceuticals, TG Therapeutics, Novalgen Limited, Kite Pharma, and AbbVie for SAP’s participation in consulting activities/advisory board meetings. NEK: Research funding has been provided to the institution from AbbVie, Acerta Pharma, Astra Zeneca, Merck, Vincerx for which NEK is a principal investigator. NEK has also participated as a member of the Data and Safety Monitoring Board for AstraZeneca, BMS-Celgene, Dren Bio. He has also participated in Advisory Board meetings of AbbVie, Astra Zeneca, Beigene, Dava Oncology, Janssen, Pharmacyclics. SSK: is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis), Humanigen (through Mayo Clinic), Mettaforge (through Mayo Clinic), and MustangBio (through Mayo Clinic), and Chymal therapeutics (through Mayo Clinic). SSK is an inventor on patents that are licensed to Immix Biopharma. Sponsored Research Funding provided to the from Kite, Gilead, Juno, BMS, Novartis, Humanigen, MorphoSys, Tolero, Sunesis/Viracta, LifEngine Animal Health Laboratories Inc., and Lentigen. SSK has participated in advisory meetings with Kite/Gilead, Calibr, Luminary Therapeutics, Humanigen, Juno/BMS, Capstan Bio, and Novartis. SSK has served on the data safety and monitoring board with Humanigen and Carisma. SSK has severed a consultant for Torque, Calibr, Novartis, Capstan Bio, BMS, Carisma, and Humanigen. TDS: Research funding has been provided to the institution from Pharmacyclics, Janssen, Genentech, Glaxo-SmithKline, Celgene, Cephalon, and Hospira for which TDS is a principal investigator. All others report no conflict of interest.
